Analysis of the NefIgArd Part A Study Confirms Nefecon Modulates Proteins Involved in the Intestinal Immune Network for IgA Production

免疫系统 免疫学 生物 细胞生物学
作者
Róisín Clare Thomas,Nadia Nawaz,Karen Molyneux,Jonathan Barratt
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:34 (11S): 976-976
标识
DOI:10.1681/asn.20233411s1976b
摘要

Background: Nefecon, the targeted release formulation of budesonide, is delivered to the gut-associated lymphoid tissue (GALT) of the terminal ileum, a major site of immunoglobulin A (IgA) production. Results from the Phase 2b NEFIGAN and Phase 3 NefIgArd trials demonstrated that treatment with 16 mg/day Nefecon significantly reduces proteinuria and loss of estimated glomerular filtration rate compared with placebo. A number of serum biomarkers have been measured in the 2 trials and many of those identified to be modulated by Nefecon in the Phase 2b study have now been validated in Part A of the NefIgArd study. The aim of this study was to determine biological pathways modulated by Nefecon treatment using the data currently available from the Part A biomarker analysis program. Methods: NefIgArd is a Phase 3 double-blind, randomized, controlled clinical trial designed to determine the efficacy of Nefecon in patients with immunoglobulin A nephropathy (IgAN) at high risk of progressive kidney disease despite optimized supportive care. The trial comprised 9 months of treatment with placebo or Nefecon 16 mg/day, and a 3-month (Part A) or 15-month (Part B) off-drug observational follow-up period. An interactome analysis was performed incorporating all serum proteins significantly modulated by treatment with Nefecon 16 mg/day in Part A of the NefIgArd study using the STRING protein-protein interactions database, which contains known and predicted protein interactions, to determine which biological processes and pathways are modulated by Nefecon treatment. Results: Consistent with the Phase 2b findings, functional analysis demonstrated that serum biomarkers significantly modulated by Nefecon treatment in Part A of the NefIgArd trial are enriched for proteins involved in the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway database for intestinal immune network for IgA production, and biological processes involved in B cell activation control, indicating the mechanism of action of Nefecon is, at least in part, driven by an effect within the GALT. Conclusions: These findings support a disease modifying effect of Nefecon at the ileal mucosal surface and a direct effect on the ileal GALT, further strengthening the link between the gut and the kidneys in IgAN. Funding: Commercial Support - Calliditas
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
acadedog完成签到,获得积分10
1秒前
deardorff发布了新的文献求助20
2秒前
2秒前
星辰大海的应助被谨慎的秋烟采纳,获得30
3秒前
4秒前
佳loong完成签到,获得积分10
5秒前
LuoYR@SZU完成签到,获得积分10
5秒前
5秒前
费劲来到这的Rua完成签到,获得积分10
5秒前
小未来完成签到,获得积分10
6秒前
6秒前
小林子完成签到 ,获得积分10
7秒前
7秒前
七七完成签到,获得积分10
8秒前
jsdiohfsiodhg完成签到,获得积分10
8秒前
chenmianyuan完成签到 ,获得积分10
9秒前
10秒前
11秒前
tian完成签到,获得积分10
11秒前
cosine发布了新的文献求助10
12秒前
喜悦的绫完成签到 ,获得积分10
12秒前
13秒前
14秒前
科研小虫完成签到,获得积分10
15秒前
Lewis完成签到 ,获得积分10
15秒前
小蘑菇的应助被科研通管家采纳,获得10
16秒前
wanci的应助被科研通管家采纳,获得10
16秒前
CipherSage的应助被科研通管家采纳,获得10
16秒前
Akim的应助被科研通管家采纳,获得30
16秒前
guamo完成签到,获得积分10
16秒前
16秒前
kiluto完成签到,获得积分10
17秒前
17秒前
烟花的应助被科研通管家采纳,获得10
17秒前
CAOHOU的应助被科研通管家采纳,获得10
17秒前
星辰大海的应助被科研通管家采纳,获得10
17秒前
天天快乐的应助被科研通管家采纳,获得10
17秒前
王大橙子发布了新的文献求助10
17秒前
所所的应助被荣荣采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621